Victory Capital Management Inc. reduced its position in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 20.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,596 shares of the biopharmaceutical company’s stock after selling 1,952 shares during the period. Victory Capital Management Inc.’s holdings in Agios Pharmaceuticals were worth $270,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AGIO. Pearl River Capital LLC acquired a new position in shares of Agios Pharmaceuticals in the 1st quarter valued at about $32,000. Carroll Financial Associates Inc. acquired a new position in Agios Pharmaceuticals during the 1st quarter worth approximately $48,000. Advisor Group Inc. lifted its position in Agios Pharmaceuticals by 551.3% during the 4th quarter. Advisor Group Inc. now owns 1,244 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 1,053 shares in the last quarter. Great West Life Assurance Co. Can acquired a new position in Agios Pharmaceuticals during the 4th quarter worth approximately $186,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Agios Pharmaceuticals by 17.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,373 shares of the biopharmaceutical company’s stock worth $191,000 after acquiring an additional 796 shares in the last quarter. 97.73% of the stock is currently owned by institutional investors and hedge funds.
AGIO has been the topic of several recent research reports. Guggenheim boosted their price target on Agios Pharmaceuticals from $60.00 to $66.00 and gave the stock a “buy” rating in a research report on Monday, June 15th. Zacks Investment Research downgraded Agios Pharmaceuticals from a “buy” rating to a “hold” rating and set a $56.00 price objective on the stock. in a report on Tuesday, June 16th. Canaccord Genuity restated a “buy” rating and set a $72.00 price objective on shares of Agios Pharmaceuticals in a report on Friday, May 1st. Barclays assumed coverage on Agios Pharmaceuticals in a report on Wednesday, March 4th. They set an “equal weight” rating and a $50.00 price objective on the stock. Finally, Cowen restated a “buy” rating on shares of Agios Pharmaceuticals in a report on Wednesday, March 4th. Four equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $68.62.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.67) by $1.08. Agios Pharmaceuticals had a negative return on equity of 63.85% and a negative net margin of 205.20%. The business had revenue of $87.10 million during the quarter, compared to the consensus estimate of $31.12 million. During the same period in the previous year, the business earned ($1.59) EPS. The business’s quarterly revenue was up 188.4% on a year-over-year basis. As a group, equities analysts predict that Agios Pharmaceuticals Inc will post -4.67 earnings per share for the current year.
In related news, insider Christopher Bowden sold 3,583 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $50.01, for a total transaction of $179,185.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.16% of the stock is owned by corporate insiders.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
See Also: Are analyst ratings accurate?
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.